Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Bio-Path Holdings's Total Liabilities for the quarter that ended in Mar. 2026 was $9.16 Mil. Bio-Path Holdings's Total Assets for the quarter that ended in Mar. 2026 was $0.68 Mil.
Therefore, Bio-Path Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 13.54.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Bio-Path Holdings Liabilities-to-Assets Related Terms
Bio-Path Holdings Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Bio-Path Holdings's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPTH vs AZTR, CLDI, BBLG: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Bio-Path Holdings's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Path Holdings Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Bio-Path Holdings's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Bio-Path Holdings's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Path Holdings (BPTH) has a Liabilities-to-Assets of 13.54 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Bio-Path Holdings and its competitors.
Is Bio-Path Holdings' Liabilities-to-Assets too high?
Bio-Path Holdings' current Liabilities-to-Assets is 13.54.
How does Bio-Path Holdings' Liabilities-to-Assets compare to AZTR and CLDI?
Bio-Path Holdings' Liabilities-to-Assets of 13.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Bio-Path Holdings and its competitors. Bio-Path Holdings's current Liabilities-to-Assets is 13.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current Liabilities-to-Assets of 13.54. The current Liabilities-to-Assets is 13.54. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current Liabilities-to-Assets is 13.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BPTH has been successfully added to your 
